Tildrakizumab in Practice: Adherence and Clinical Takeaways

An expert discusses how health care provider administration may improve adherence to tildrakizumab. The meta-analysis confirms its real-world efficacy, safety, and quality of life benefits, supporting clinical use. These findings may influence payer decisions by reinforcing its value and long-term effectiveness in psoriasis care.

EP: 1.Real-World Insights on Tildrakizumab

Now Viewing

EP: 2.Tildrakizumab in Practice: Adherence and Clinical Takeaways

EP: 3.The VISIBLE Study: Understanding Comorbidities in Psoriasis Across All Skin Tones

EP: 4.Comparing Biologic Treatment Patterns: Tildrakizumab vs Ustekinumab

EP: 5.Switching to Biosimilars for the Management of Psoriasis

Video content above is prompted by the following:

• Since tildrakizumab is administered by health care providers, do you think this leads to better adherence of the therapy?
• What are your main takeaways from this abstract, and how will you carry this over to your clinical practice?
• How do you believe these abstract results will influence payer decisions?

Related Videos